P88.02 SDC4-ROS1 Fusion as a Mechanism of Acquired Resistance in EGFR-Mutant Lung Adenocarcinoma

The enhanced understanding of the biological mechanisms underlying non-small cell lung cancer (NSCLC) development and progression has led to targeted therapies becoming an increasingly important strategy for the treatment of NSCLC. Several clinical trials have demonstrated that most NSCLC patients with specific epidermal growth factor receptor (EGFR) mutations respond significantly to EGFR tyrosine kinase inhibitors (TKIs). However, the majority of patients who initially respond to EGFR-TKI therapies eventually develop drug resistance, often within a year.